Ligand Pharmaceuticals Incorporated share price logo

Ligand Pharmaceuticals Incorporated

NASDAQ: LGND

Mid Cap

$227.50

-1.95

(-0.85%)

as on

Ligand Pharmaceuticals Incorporated Stock Performance

as on May 2, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $226.47
    $236.22
    downward going graph

    0.45%

    Downside

    3.83%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $98.89
    $247.38
    downward going graph

    56.53%

    Downside

    8.74%

    Upside

    downward going graph

Ligand Pharmaceuticals Incorporated share price movements today

Previous Close
$229.45
Open
$229.87
Volume
254.4K
Day's Low - High
$226.47 - $236.22
52 Week Low - High
$98.89 - $247.38

Ligand Pharmaceuticals Incorporated Historical Returns

1 Month Return
+ 13.95 %
3 Month Return
+ 14.91 %
1 Year Return
+ 107.92 %
3 Year Return
+ 204.59 %
5 Year Return
+ 55.9 %

Ligand Pharmaceuticals Incorporated Stock Fundamentals & Key Indicators

Check Ligand Pharmaceuticals Incorporated market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.8B

EPS (TTM)

9.148

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

1.03%

PE Ratio (TTM)

37.04

Industry PE ratio

-12.802264150943396

PEG Ratio

1.5271

EBITDA

81.0M

Revenue (TTM)

268.1M

Profit Margin

46.42%

Return On Equity TTM

13.47%

Ligand Pharmaceuticals Incorporated Stock Valuation

Track how Ligand Pharmaceuticals Incorporated P/E has moved over time to understand its valuation trends.

Ligand Pharmaceuticals Incorporated in the last 5 years

  • Overview

  • Trends

Lowest (9.67x)

December 31, 2023

Industry (-12.80x)

May 2, 2026

Today (37.04x)

May 2, 2026

Highest (36.98x)

March 31, 2026

LowHigh

Today’s Price to Earnings Ratio: 37.04x

Ligand Pharmaceuticals Incorporated vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Ligand Pharmaceuticals Incorporated with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$2.8B55.9%37.0446.42%
BUY$41.3B110.54%77.5712.55%
BUY$108.7B94.28%27.9332.94%
NA$32.7BNA118.495.37%
BUY$74.1B45.73%17.2729.65%

Stock Returns calculator for Ligand Pharmaceuticals Incorporated Stock including INR - Dollar returns

The Ligand Pharmaceuticals Incorporated stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ligand Pharmaceuticals Incorporated investment value today

Current value as on today

₹2,33,519

Returns

₹1,33,519

(+133.52%)

Returns from Ligand Pharmaceuticals Incorporated Stock

₹1,07,971 (+107.97%)

Dollar Impact

₹25,548 (+25.55%)

Analyst Recommendation on Ligand Pharmaceuticals Incorporated Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Ligand Pharmaceuticals Incorporated. Average target price of $268

Ligand Pharmaceuticals Incorporated Share Price Target

Get share price movements and forecasts by analysts on Ligand Pharmaceuticals Incorporated.

What analysts predicted

15.11%UPSIDE

Target Price

$268

Current Price

$227.5

Analyzed by

11 Analysts

Target

$268.00

Ligand Pharmaceuticals Incorporated target price $268, a slight upside of 15.11% compared to current price of $227.5. According to 11 analysts rating.

Ligand Pharmaceuticals Incorporated Stock’s Investor Sentiment and Interest

Search interest for Ligand Pharmaceuticals Incorporated Stock has decreased by -52% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-52% versus previous 30 day period

Ligand Pharmaceuticals Incorporated Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
32
28
30
41
51
42
45
47
115
59
Gross Profit
29
26
19
56
39
39
40
44
90
85
Operating Income
3
-3
2
-19
3
-9
-36
8
54
20
EBITDA
-3
26
122
-55
3
-29
-40
20
149
66
Interest Expense
0
0
0
1
0
0
0
1
0
1
Depreciation
8
8
8
8
8
8
8
8
8
8
Income Before Tax
-12
17
113
-65
-6
-39
-50
11
141
56
Income Tax Expense
-1
-1
27
-13
0
-8
-7
6
23
11
Net Income
-10
18
86
-51
-7
-31
-42
4
117
44
Net Profit Margin
-31.26%
64.72%
278.07%
-124.99%
-13.84%
-72.62%
-93.64%
10.18%
101.57%
75.06%

Ligand Pharmaceuticals Incorporated Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
108
141
251
120
163
241
196
131
167
268
Gross Profit
103
135
245
108
133
179
143
96
156
261
Operating Income
43
68
163
807
37
103
3
11
-22
47
EBITDA
55
81
238
876
56
142
81
100
40
192
Interest Expense
12
11
48
35
27
19
1
0
3
4
Depreciation
-
11
14
43
27
47
34
37
35
33
Income Before Tax
7
57
173
796
1
72
36
63
2
158
Income Tax Expense
10
44
30
167
-5
-4
41
9
6
34
Net Income
-1
12
143
629
-2
57
-33
52
-4
124
Net Profit Margin
-1.50%
8.90%
57.00%
523.19%
-1.82%
23.66%
-17.00%
39.72%
-2.41%
46.42%

Ligand Pharmaceuticals Incorporated Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
18
86
-51
-7
-31
-42
4
117
44
Operating Cash Flow
7
18
13
36
28
-25
15
13
45
Investing Cash Flow
-10
-3
-54
-46
-38
4
-10
-353
-18
Financing Cash Flow
6
12
9
55
20
-4
14
409
8
Change in Cash
3
27
-31
45
8
-24
19
71
35

Ligand Pharmaceuticals Incorporated Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
12
143
629
-2
57
-33
52
-4
124
Operating Cash Flow
93
194
-29
54
78
137
49
97
49
Investing Cash Flow
-84
-423
466
231
30
163
-11
-143
-377
Financing Cash Flow
-7
328
-485
-310
-137
-275
-59
97
428
Change in Cash
1
99
-47
-24
-28
25
-22
49
102

Global Institutional Holdings in Ligand Pharmaceuticals Incorporated

Funds
Holdings
Ashford Capital Management Inc
1.55%
Tudor Investment Corp Et AL
79.65%
State Street Corp
3.79%
Northern Trust Corp
1.42%
The Goldman Sachs Group Inc
1.84%

Insights on Ligand Pharmaceuticals Incorporated

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, LGND stock has moved up by 204.6%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, LGND has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, LGND has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 115.46M → 59.66M (in $), with an average decrease of 48.3% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 117.27M → 44.78M (in $), with an average decrease of 61.8% per quarter

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
OrganisationLigand Pharmaceuticals Incorporated
Headquarters555 Heritage Drive, Jupiter, FL, United States, 33458
IndustryBiotechnology
CEOMr. Todd C. Davis Ph.D.
E-voting on sharesClick here to vote

Key Management of Ligand Pharmaceuticals Incorporated

Name

Title

Mr. Todd C. Davis Ph.D.

CEO & Director

Mr. Octavio Espinoza

Chief Financial Officer

Mr. Andrew T. Reardon J.D.

Chief Legal Officer & Secretary

Mr. Paul J. Hadden

Senior Vice President of Investments & Business Development

Dr. Keith Marschke Ph.D.

Senior Vice President of Biology & Scientific Affairs

Dr. Vincent D. Antle Ph.D.

Senior Vice President of Technical Operations & QA - Capitsol

FAQs

What is Ligand Pharmaceuticals Incorporated share price today?

Ligand Pharmaceuticals Incorporated share price today is $227.5 as on at the close of the market. Ligand Pharmaceuticals Incorporated share today touched a day high of $236.22 and a low of $226.47.

What is the 52 week high and 52 week low for Ligand Pharmaceuticals Incorporated share?

Ligand Pharmaceuticals Incorporated share touched a 52 week high of $247.38 on and a 52 week low of $98.89 on . Ligand Pharmaceuticals Incorporated stock price today i.e. is closed at $227.5,which is 8.04% down from its 52 week high and 130.05% up from its 52 week low.

What is Ligand Pharmaceuticals Incorporated's market capitalisation today?

Ligand Pharmaceuticals Incorporated market capitalisation is $0.00T as on .

How to invest in Ligand Pharmaceuticals Incorporated Stock (LGND) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Ligand Pharmaceuticals Incorporated on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ligand Pharmaceuticals Incorporated Shares that will get you 0.0066 shares as per Ligand Pharmaceuticals Incorporated share price of $227.5 per share as on May 2, 2026 at 1:29 am IST.

What is the minimum amount required to buy Ligand Pharmaceuticals Incorporated Stock (LGND) from India?

Indian investors can start investing in Ligand Pharmaceuticals Incorporated (LGND) shares with as little as ₹94.91 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.10 in Ligand Pharmaceuticals Incorporated stock (as per the Rupee-Dollar exchange rate as on ). Based on Ligand Pharmaceuticals Incorporated share’s latest price of $227.5 as on May 2, 2026 at 1:29 am IST, you will get 0.0440 shares of Ligand Pharmaceuticals Incorporated. Learn more about fractional shares .

What are the returns that Ligand Pharmaceuticals Incorporated has given to Indian investors in the last 5 years?

Ligand Pharmaceuticals Incorporated stock has given 55.9% share price returns and 28.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?